Status:
UNKNOWN
Elevated Initial APRI Value Was Associated With SALD
Lead Sponsor:
Chinese Medical Association
Conditions:
Liver Dysfunction
Sepsis-associated Liver Dysfunction
Eligibility:
All Genders
18-90 years
Brief Summary
Sepsis, characterized by severe organ dysfunction related to a dysregulated immune response to infection, is often life-threatening in clinical settings. Sepsis can progress to multiple organ dysfunct...
Detailed Description
We included adult sepsis patients (≥18 years) as study participants, but only those who had data available for their first hospitalization and first ICU admission were enrolled in our study, if they h...
Eligibility Criteria
Inclusion
- adult sepsis patients (≥18 years)
Exclusion
- all types of chronic liver disease;
- viral hepatitis;
- primary acute cholangiopathies;
- cholecystitis;
- hepatic infarction;
- liver necrosis;
- liver trauma;
- length of ICU stay \< 24 hours;
- Patients without simultaneous AST and PLT data in the first 24 hours after ICU admission.
Key Trial Info
Start Date :
January 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2023
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT05999331
Start Date
January 1 2019
End Date
September 30 2023
Last Update
August 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of General Surgery of Jinling Hospital
Nanjing, Jiangsu, China, 210002